<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pediatric Hematology/Oncology and Immunopathology</journal-id><journal-title-group><journal-title xml:lang="en">Pediatric Hematology/Oncology and Immunopathology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы гематологии/онкологии и иммунопатологии в педиатрии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-1708</issn><issn publication-format="electronic">2414-9314</issn><publisher><publisher-name xml:lang="en">Fund Doctors, Innovations, Science for Children</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">481</article-id><article-id pub-id-type="doi">10.24287/1726-1708-2021-20-1-54-57</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bone changes during and after treatment of childhood acute lymphoblastic leukaemia</article-title><trans-title-group xml:lang="ru"><trans-title>Bone changes during and after treatment of childhood acute lymphoblastic leukaemia</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ragab</surname><given-names>S.</given-names></name><address><country country="EG">Egypt</country></address><bio xml:lang="en"><p>Menoufia </p></bio><bio xml:lang="ru"><p>Menoufia</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Montaser</surname><given-names>B.</given-names></name><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Menoufia </p></bio><bio xml:lang="ru"><p>Menoufia</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>El-Ashmawy</surname><given-names>N.</given-names></name><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Menoufia </p></bio><bio xml:lang="ru"><p>Menoufia</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>El-Hawy</surname><given-names>M.</given-names></name><address><country country="RU">Russian Federation</country></address><bio><p>Pediatrics Department, Faculty of Medicine, </p><p>Shebin el Kom, 32511 Menoufia</p></bio><email>mahmodelhawy18@yahoo.com</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Menoufia University</institution></aff><pub-date date-type="pub" iso-8601-date="2021-04-21" publication-format="electronic"><day>21</day><month>04</month><year>2021</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>54</fpage><lpage>57</lpage><history><date date-type="received" iso-8601-date="2021-04-16"><day>16</day><month>04</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-04-16"><day>16</day><month>04</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, «D. Rogachev NMRCPHOI»</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">«D. Rogachev NMRCPHOI»</copyright-holder><copyright-holder xml:lang="ru">ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://hemoncim.com/jour/article/view/481">https://hemoncim.com/jour/article/view/481</self-uri><abstract xml:lang="en"><p>Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a survival rate of 80%. Major complications of leukemia include osteoporosis that requires both a clinically significant fracture history and low bone mineral density (BMD). The present study aims to assess BMD among acute lymphoblastic leukemia patients and survivors using dual-energy x-ray absorptiometry and serum insulin growth factor binding protein 3. The study was approved by the Independent Ethics Committee and the Scientific Council of the Menoufia University, Egypt. Thirty patients with ALL and thirty survivors who were diagnosed with ALL but completely recovered were enrolled in this study. Sex and age matched normal controls while full history was taken. Patients and survivors were examined for anthropometric measurement. Laboratory including serum IGFBP3and dual-energy x-ray absorptiometry was done for all. It has been found out that patients and survivors showed a markedly lower BMD than normal population but no history of fracture was found in survivors. In this study, the prevalence of low BMD is 26/30 (86.6%) patients and 25/30 (83.3%) survivors. Also, there was a statistically significant decrease of DEXA scan measures in patients and survivors groups than the control group with a statistically significant decrease in both BMD and Z- score measures in patients and survivors groups than control group. Patients and long-term survivors of childhood ALL are at risk for morbidity associated with low BMD. They may benefit from interventions to optimize bone health as they age. </p></abstract><trans-abstract xml:lang="ru"><p>Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with a survival rate of 80%. Major complications of leukemia include osteoporosis that requires both a clinically significant fracture history and low bone mineral density (BMD). The present study aims to assess BMD among acute lymphoblastic leukemia patients and survivors using dual-energy x-ray absorptiometry and serum insulin growth factor binding protein 3. The study was approved by the Independent Ethics Committee and the Scientific Council of the Menoufia University, Egypt. Thirty patients with ALL and thirty survivors who were diagnosed with ALL but completely recovered were enrolled in this study. Sex and age matched normal controls while full history was taken. Patients and survivors were examined for anthropometric measurement. Laboratory including serum IGFBP3and dual-energy x-ray absorptiometry was done for all. It has been found out that patients and survivors showed a markedly lower BMD than normal population but no history of fracture was found in survivors. In this study, the prevalence of low BMD is 26/30 (86.6%) patients and 25/30 (83.3%) survivors. Also, there was a statistically significant decrease of DEXA scan measures in patients and survivors groups than the control group with a statistically significant decrease in both BMD and Z- score measures in patients and survivors groups than control group. Patients and long-term survivors of childhood ALL are at risk for morbidity associated with low BMD. They may benefit from interventions to optimize bone health as they age. </p></trans-abstract><kwd-group xml:lang="en"><kwd>acute lymphoblastic leukemia</kwd><kwd>osteoporosis</kwd><kwd>survivors</kwd><kwd>bone mineral density</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>acute lymphoblastic leukemia</kwd><kwd>osteoporosis</kwd><kwd>survivors</kwd><kwd>bone mineral density</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Seiter K., Sarkodee-Adoo C., Talavera F., Sacher R.A., Besa E.C., eds. Acute Lymphoblastic Leukemia. Medscape Reference. WebMD. Retrieved 17 April 2014.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lin J.T., Lane J.M. Osteoporosis: a review. Clin Orthop Relat Res 2004; 425: 126–34.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>NIH Consensus Development Panel on Osteoporosis. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–95.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Haddy T.B., Adde M.A., McCalla J. Late effects in longterm survivors of highgrade non-Hodgkin’s lymphomas. J Clin Oncol 1998; 16: 2070–9.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Kishi S., Griener J., Cheng С., Das S., Cook E.H., Pei D., et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21 (16): 3084–91.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Pui C.H., Sandlund J.T., Pei D. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104 (9): 2690–6.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004; 7: 17–26.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Frank R., Horacio P., Linda D.M., Raoul H.E., Richard C., Henderson C.M., et al. Fracture Prediction and the Definition of Osteoporosis in Children and Adolescents: The ISCD Pediatric Offi cial Positions. J Clin Densitom 2007; 1: 22–8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lewiecki E.M., Baim S., Binkley N., Bilezikian J.P., Kendler D.L. Report of the International Society for Clinica Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J 2008: 101: 735–9.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Muszynska-Roslan K., Panasiuk A., Latoch E., Krawczuk-Rybak M., Konstantynowicz J. Little evidence of a low bone mass in acute lymphoblastic leukemia survivors. J Clin Densitom 2012; 15: 108–15.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kang M.J., Lim J.S. Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management. Korean J Pediatr 2013; 56 (2): 60–7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Kaste S.C., Jones-Wallace D., Rose S.R., Boyett J.M., Lustig R.H., Rivera G.K., et al. Bone mineral decrements in survivors of childhood acute lymphoblastic leukemia: frequency of occurrence and risk factors for their development. Leukemia 2001; 15: 728–34.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Hoorweg-Nijman J.J.G., Kardos G., Roost J.C. Bone mineral density and markers of bone turnover in young adult survivors of childhood lymphoblastic leukemia. Clin Endocrinol 1999; 50: 237–44.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Van der Sluis I.M., van den HeuvelEibrink M.M., Hahlen K., Krenning E.P., de Muinck Keizer-Schrama S.M. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Med Pediatr Oncol 2000; 35: 415–20.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Reisi N., Iravani P., Raeissi P., Kelishadi R. Vitamin D and Bone Minerals Status in the Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. Int J Prev Med 2015; 6: 87.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sebestyen J.F., Srivastava T., Alon U.S. Bisphosphonates use in children. Clin Pediatr (Phila) 2012; 51: 1011–24.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Pfeilschifter J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18: 1570–93.</mixed-citation></ref></ref-list></back></article>
